Clinical study on the effects of diacerein and diacerein combined with chondroitin sulfate on canine hip osteoarthritis [Diacerein ve kondroitin sülfat eklenmiş diacerein'in köpek kalça osteoartritisindeki etkileri üzerine klinik bir çali{dotless}şma]

This study aimed to evaluate the effects of diacerein (dar) and dar combined with chondroitin sulfate (cs) for treatment of canine hip osteoarthritis (oa) in a 6-month clinical trial. client-owned dogs included in the study consisted of 27 males and 25 females,aged 59.43±17.05 months old and weighing 17.63±5.19 kg. the dogs were randomly divided into five groups: dar50 (administration of dar 50 mg daily); dar100 (dar 100 mg daily); dar50/cs (dar 50 mg + cs 525 mg daily); dar100/cs (dar 100 mg + cs 525 mg daily); and cs (cs 525 mg daily). dogs were re-examined monthly for 6 months after initiation of treatment. the assessment protocol included clinical scores and radiographic findings. blood samples were collected three times (pre-treatment,and after 3 and 6 months) for evaluation of the serum biomarker,cs-wf6. dogs treated with dar showed statistically significant improvements (p<0.05) in lameness,joint mobility,pain on palpation,weight-bearing,and overall clinical score at 3,6,5,4,and 4 months,respectively,after the start of treatment. side effects,including diarrhea and dark-colored urine,were found in all groups receiving dar. after the 3rd month,the level of serum cs-wf6 in the cs group was significantly elevated (p<0.05),while the other four groups showed a significant decrease (p<0.05). the results showed that dar 50 or 100 mg had a similarly positive therapeutic effect on dogs with osteoarthritis. the use of dar alone or in combination with cs resulted in decreased degradation of oa cartilage.